Many Multiple Myeloma Therapies Effective in Older Patients
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.
AML Risk Significantly Increased After Radioactive Iodine Treatment for Thyroid Cancer
Radioactive iodine treatment for low-risk thyroid cancer is associated with nearly twice the risk of developing acute myeloid leukemia.
Administration of a PARP inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life during treatment.
Frontline Therapy May Become New Standard of Care in EGFR+ NSCLC
Patients with advanced, EGFR-mutant NSCLC lived almost twice as long without disease progression after initial treatment with an EGFR inhibitor compared with standard of care TKI therapy.
High-Risk Prostate Cancer Effectively Managed With Two Novel Therapies
Patients with high-risk prostate cancer initiating long-term hormone therapy will likely benefit from two new treatments with comparable efficacy and safety profiles.
Treatment-Related Costs Among Patients With Metastatic Bladder Cancer
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
Aggressive Cancer Care at End of Life Remains Persistent Despite Increased Palliative Care
A recent study shows that the increase in integrated palliative care does not appear to have altered aggressive cancer care at the end of life.
